- Report
- July 2022
- 40 Pages
Ireland
From €1373EUR$1,500USD£1,167GBP
- Report
- July 2022
- 40 Pages
Germany
From €1373EUR$1,500USD£1,167GBP
- Report
- July 2022
- 40 Pages
France
From €1373EUR$1,500USD£1,167GBP
- Report
- May 2022
- 80 Pages
Africa
From €1831EUR$2,000USD£1,556GBP
From €109EUR$119USD£93GBP
- Report
- November 2021
- 747 Pages
Global
From €3662EUR$4,000USD£3,112GBP
- Report
- December 2023
- 248 Pages
Global
From €2288EUR$2,499USD£1,944GBP
€3268EUR$3,570USD£2,777GBP
- Book
- November 2024
- 464 Pages
- Book
- March 2024
- 496 Pages
- Book
- August 2022
- 320 Pages
- Book
- February 2020
- 202 Pages
- Book
- July 2018
- 360 Pages
- Book
- August 2023
Global
- Book
- October 2020
- 288 Pages

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more